A new class of insulin taken once a week could be just as effective for managing blood sugar in people with type 1 and type 2 diabetes as daily injections, according to trials. Reducing jabs “could lessen the burden” for people with the conditions, experts said, although one study found there were higher rates of low blood sugar among type 1 diabetics. Researchers suggested “additional evaluation” should be made when starting these patients on the drug, and while deciding on their optimal dose. Findings from two US trials of efsitora, developed by pharma company Eli Lilly, have been presented …